"I, N" . . . "10.1111/ane.12001" . "10"^^ . "Gee, M." . "Objectives Evaluate interim long-term tolerability, safety and efficacy of adjunctive perampanel, a novel alpha-amino-3-hydroxy-5-methyl-5-isoxazolepropionic acid (AMPA)-receptor antagonist, in patients with refractory partial-onset seizures. Materials and methods Study 207, an open-label extension (OLE) study (ClinicalTrials.gov identifier: NCT00368472), enrolled patients (1870 years) who completed one of two randomized, placebo-controlled, dose-escalation Phase II studies. The OLE Treatment Phase comprised a 12-week Titration Period (2 mg increments of perampanel every 2 weeks to 12 mg/day, maximum) and a Maintenance Period, during which patients continued treatment up to a planned maximum of 424 weeks ( 8 years). Interim analysis data cut-off date was 1 December, 2010. Results Of 180 patients completing the Phase II studies, 138 enrolled in study 207. At the time of interim analyses (approximately 4 years after study start), over a third (n = 53, 38.4%) remained on perampanel; 41." . . . "000308205500008" . . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Objectives Evaluate interim long-term tolerability, safety and efficacy of adjunctive perampanel, a novel alpha-amino-3-hydroxy-5-methyl-5-isoxazolepropionic acid (AMPA)-receptor antagonist, in patients with refractory partial-onset seizures. Materials and methods Study 207, an open-label extension (OLE) study (ClinicalTrials.gov identifier: NCT00368472), enrolled patients (1870 years) who completed one of two randomized, placebo-controlled, dose-escalation Phase II studies. The OLE Treatment Phase comprised a 12-week Titration Period (2 mg increments of perampanel every 2 weeks to 12 mg/day, maximum) and a Maintenance Period, during which patients continued treatment up to a planned maximum of 424 weeks ( 8 years). Interim analysis data cut-off date was 1 December, 2010. Results Of 180 patients completing the Phase II studies, 138 enrolled in study 207. At the time of interim analyses (approximately 4 years after study start), over a third (n = 53, 38.4%) remained on perampanel; 41."@en . "Perampanel Study 207: long-term open-label evaluation in patients with epilepsy" . "Squillacote, D." . "7"^^ . . . "RIV/00216224:14740/12:00073090" . "4" . . "a-amino-3-hydroxy-5-methyl-5-isoxazolepropionic acid; antiepileptic drugs; epilepsy; glutamate; long-term safety; open-label extension; perampanel; post-synaptic"@en . "Vaiciene-Magistris, N." . "Perampanel Study 207: long-term open-label evaluation in patients with epilepsy"@en . "0001-6314" . . "14740" . . "Rektor, Ivan" . . . "Kumar, D." . "Krauss, G. L." . "RIV/00216224:14740/12:00073090!RIV14-MSM-14740___" . "2"^^ . "158140" . "Perampanel Study 207: long-term open-label evaluation in patients with epilepsy" . . . . "Biton, V." . "[F9F5C50880D1]" . . "Klapper, J. A." . . . "Perampanel Study 207: long-term open-label evaluation in patients with epilepsy"@en . "Kuba, Robert" . . "Acta Neurologica Scandinavica" . . . "Bar, M." . "126" . .